Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
4.050
-0.200 (-4.71%)
At close: Apr 28, 2026, 4:00 PM EDT
4.050
0.00 (0.00%)
Pre-market: Apr 29, 2026, 4:02 AM EDT
Zentalis Pharmaceuticals Employees
Zentalis Pharmaceuticals had 106 employees as of December 31, 2025. The number of employees decreased by 60 or -36.14% compared to the previous year.
Employees
106
Change (1Y)
-60
Growth (1Y)
-36.14%
Revenue / Employee
n/a
Profits / Employee
-$1,293,019
Market Cap
287.27M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| LENZ Therapeutics | 152 |
| Coherus Oncology | 147 |
| AC Immune | 122 |
| C4 Therapeutics | 104 |
| Editas Medicine | 87 |
| Compugen | 75 |
| Cybin | 50 |
ZNTL News
- 7 days ago - Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer - GlobeNewsWire
- 11 days ago - Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026 - GlobeNewsWire
- 18 days ago - What's Behind The Surge In Zentalis Stock? - Benzinga
- 19 days ago - Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer - GlobeNewsWire
- 27 days ago - Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates - GlobeNewsWire
- 6 weeks ago - Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026 - GlobeNewsWire
- 7 weeks ago - Zentalis Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026 - Transcripts